Study programme abroad Sample Clauses

The 'Study programme abroad' clause defines the terms and conditions under which a student may participate in an educational program outside their home country. It typically outlines eligibility requirements, application procedures, and the responsibilities of both the student and the institution, such as credit transfer policies and financial obligations. By clearly establishing these parameters, the clause ensures that both parties understand their commitments and helps prevent misunderstandings regarding academic recognition and logistical arrangements during the period abroad.
Study programme abroad. No. Component title (as indicated in the course catalogue) at the receiving institution Semester [autumn / spring] Number of ECTS credits to be awarded by the receiving institution upon successful completion Total: …………
View SourceView Similar (3)
Study programme abroad. Table B - Group of educational components in the student's degree that would normally be completed at the sending institution and which will be replaced by the study abroad
View Source
Study programme abroad. Course unit code (if any) Course unit at the receiving institution (as indicated in the course catalogue) Number of ECTS credits to be awarded by the receiving institution Total: ………………… Web link(s) to the course catalogue at the receiving institution: Course unit at the receiving institution (as indicated in the course catalogue) Number of ECTS credits Equivalent course unit at the University of Gdansk (as indicated in the course catalogue) Number of ECTS credits Provisions that will apply if some educational components would not be successfully completed: Such provisions are established at each faculty separately and individually with each student. Language competence of the student The level of language competence in language of instruction that the student already has or agrees to acquire by the start of the study period is: A1  A2  B1  B2  C1  C2  Table C: Subjects the student is obliged to complete at the University of Gdansk after the mobility period (there are no equivalents at the receiving institution / completion of the subject(s) below is required to obtain the degree): Course unit Number of ECTS credits Deadline for completion Responsible person at the University of Gdansk: Faculty Coordinator Name: ..................................................... E-mail: ..................................................... Responsible person at the University of Gdansk: ▇▇▇▇/ Vice-▇▇▇▇ Name: ..................................................... E-mail: ..................................................... Responsible person at the receiving institution: Name: ..................................................... Function: .................................................... Phone number: ..................................................... E-mail: ....................................................
View Source

Related to Study programme abroad

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in ▇▇▇▇ rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Training Program It is agreed that there shall be an Apprenticeship Training Program, the provisions of which are set forth in Exhibit "D", which is attached hereto and forms part of this Agreement.

  • Programme 13.1 Within the time stated in the Contract Data, the Contractor shall submit to the Engineer for approval a Programme showing the general methods, arrangements,' order and timing for all the activities for the construction of works. 13.2 The program shall be supported with all the details regarding key personnel, equipment and machinery proposed to be deployed on the works for its execution. The contractor shall submit the list of equipment and machinery being brought to site, the list of key personnel being deployed, the list of machinery/equipment being placed in field laboratory and the location of field laboratory along with the Programme.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.